These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 37662021)

  • 1. Incremental Healthcare Costs and Outpatient Antifungal Treatment of Patients with Aspergillosis in the United States.
    Durden E; McMorrow D; Juneau P; Fowler R; Chaudhari P; Horn D
    J Health Econ Outcomes Res; 2013; 1(2):151-162. PubMed ID: 37662021
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-related and all-cause health care costs of elderly patients with gout.
    Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
    J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis.
    Chin L; Hansen RN; Carlson JJ
    J Manag Care Spec Pharm; 2020 Aug; 26(8):962-970. PubMed ID: 32715961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis.
    Almony A; Keyloun KR; Shah-Manek B; Multani JK; McGuiness CB; Chen CC; Campbell JH
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1260-1272. PubMed ID: 34464210
    [No Abstract]   [Full Text] [Related]  

  • 10. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
    Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.
    Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT; Doshi JA
    J Med Econ; 2014 Feb; 17(2):148-58. PubMed ID: 24168640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
    Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
    J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
    Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
    J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.
    Parasuraman S; Thiel E; Park J; Teschemaker A
    J Med Econ; 2023; 26(1):454-462. PubMed ID: 36883994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
    Bhowmik D; Hines DM; Intorcia M; Wade RL
    J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Burden of Commercially Insured Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States.
    Pilon D; Neslusan C; Zhdanava M; Sheehan JJ; Joshi K; Morrison L; Rossi C; Lefebvre P; Greenberg PE
    J Clin Psychiatry; 2022 Apr; 83(3):. PubMed ID: 35390231
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.
    Tencer T; Friedman HS; Li-McLeod J; Johnson K
    J Manag Care Pharm; 2007; 13(9):790-8. PubMed ID: 18062730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.